The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
James O. Armitage (Profiled Author: James Olen Armitage)
Mayo Clinic Proceedings 2012;87(2):161-171.Abstract
My favored treatment approach for patients with diffuse large B-cell lymphoma continues to evolve. Diffuse large B-cell lymphoma can now be cured in more than 50% of patients. This is a result of improved definitions of the disease, improved diagnostic capabilities, better staging and restaging techniques, a useful prognostic index to guide therapeutic decisions, and the development of increasingly effective therapies. Positron emission tomographic scans have improved the accuracy of both staging and restaging. Findings on a positron emission tomographic scan at the end of therapy are the best predictors of a good treatment outcome. Numerous subtypes of diffuse large B-cell lymphoma have been identified that require specific treatment approaches. For example, plasmablastic lymphoma typically lacks CD20 and does not benefit from treatment with rituximab. Diffuse large B-cell lymphoma originating in specific extranodal sites such as the central nervous system, testes, and skin presents special problems and requires specific treatment approaches. A subgroup of diffuse large B-cell lymphoma with a very high proliferative rate seems to have a poor outcome when treated with CHOP-R and does better with regimens used for patients with Burkitt lymphoma. New insights into the biology of these disorders are likely to further change treatment approaches. Recognition that diffuse large B-cell lymphoma is not one disease, but a variety of clinicopathologic syndromes provides the opportunity to further improve our ability to benefit patients. © 2012 Mayo Foundation for Medical Education and Research.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Ekaterina Chigrinova; Michael Mian; Yulei Shen; Timothy C. Greiner; Wing C. Chan; Julie M. Vose; Giorgio Inghirami; Annalisa Chiappella; Luca Baldini; Maurilio Ponzoni; et al.British Journal of Haematology 2011;153(4):499-503.
Keni Gu; Dennis D. Weisenburger; Kai Fu; Wing C. Chan; Timothy C. Greiner; Patricia Aoun; Lynette M. Smith; Martin Bast; Zhongfen Liu; R. Gregory Bociek; et al.Hematological Oncology 2012;30(3):143-149.
Martin L. Blakely; Richard J. Andrassy; R. Beverly Raney; James R. Anderson; Eugene S. Wiener; David A. Rodeberg; Charles N. Paidas; Thom E. Lobe; William M. CristJournal of Pediatric Surgery 2003;38(3):347-353.
Appears in this Document